Nephrogenic systemic fibrosis in Denmark - A nationwide investigation

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Elmholdt, Tina R ^a   Olesen, Anne B B ^a   Jørgensen, Bettina ^a   Kvist, Stinne ^a   Skov, Lone ^b   Thomsen, Henrik S ^c   Marckmann, Peter ^c,d   Pedersen, Michael ^a,e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DENMARK; DISEASE ASSOCIATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DENMARK; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY; SKIN;

EID: 84891906441     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082037     Document Type: Article

References (37)

1. From the Centers for Disease Control and Prevention. Fibrosing skin condition among patients with renal disease-United States and Europe, 1997-2002. JAMA 287: 838.
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000-1001. S0140-6736(00)02694-5 [pii];10.1016/S0140-6736(00)02694-5 [doi].
3. Cowper SE, Su LD, Bhawan J, Robin HS, Leboit PE (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383-393. (Pubitemid 32938907)
4. Ting WW, Stone MS, Madison KC, Kurtz K (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139: 903-906. 10.1001/archderm.139.7.903 [doi];139/7/903 [pii]. (Pubitemid 36898926)
5. Levine JM, Taylor RA, Elman LB, Bird SJ, Lavi E, et al. (2004) Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30: 569-577. 10.1002/mus.20153 [doi]. (Pubitemid 39447280)
6. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, et al. (2008) Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73: 1413-1418. ki200876 [pii];10.1038/ki.2008.76 [doi]. (Pubitemid 351770496)
7. Kay J, Bazari H, Avery LL, Koreishi AF (2008) Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 358: 827-838. 358/8/827 [pii];10.1056/NEJMcpc0708697 [doi]. (Pubitemid 351281646)
8. Sanyal S, Marckmann P, Scherer S, Abraham JL (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis-an autopsy-based review. Nephrol Dial Transplant. gfr085 [pii];10.1093/ndt/gfr085 [doi].
9. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, et al. (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245: 168-175. 2451070353 [pii];10.1148/radiol.2451070353 [doi]. (Pubitemid 47417800)
10. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, et al. (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362. ASN.2006060601 [pii];10.1681/ASN.2006060601 [doi]. (Pubitemid 44300951)
11. Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108. gfk062 [pii];10.1093/ndt/gfk062 [doi]
12. http://www.nephrology.dk/Publikationer/ Anbefalinger%20mhp%20identifikation%20af%20nyresyge%20patienter, %20der%20kan%20mist%C3%A6nkes%20for%20nefrogen%20systemisk%20fibrose%20efter%20 uds%C3%A6ttelse%20for%20gadoliniumholdig%20kontrast.pdf. Accessed November 1, 2013.
13. Marckmann P, Skov L, Rossen K, Thomsen HS (2008) Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 69: 161-168. (Pubitemid 351351062)
14. Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, et al. (2008) Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. J Nephrol 21: 324-336.
15. Furst DE, Clements PJ, Steen VD, Medsger TA, Jr., Masi AT, et al. (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25: 84-88. (Pubitemid 28060123)
16. Cowper SE, Rabach M, Girardi M (2008) Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66: 191-199. S0720-048X(08)00036- 3 [pii];10.1016/j.ejrad.2008.01.016 [doi].
17. Marckmann P, Skov L (2009) Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am 47: 833-40, vi. S0033-8389(09)00092- X [pii];10.1016/j.rcl.2009.05.004 [doi].
18. Bangsgaard N, Marckmann P, Rossen K, Skov L (2009) Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 145: 183-187. 145/2/183[pii];10.1001/archdermatol.2008.551 [doi].
19. http://www.regionmidtjylland.dk/politik/udvalg/forretningsudvalget/ visdagsorden?file = 30-11-2010/Aaben-dagsorden/Bilag/Punkt-14-Bilag-1-.PDF. Accessed November 1, 2013.
20. http://onlinelibrary.wiley.com/doi/10.1002/dat.20507/pdf. Accessed November 1, 2013.
21. Matthesen SK, Pedersen EB (2008) [Nephrogen systemic fibrosis is reported in a dialysis patient after MR-angiography with a contrast medium]. Ugeskr Laeger 170: 655. VP51901 [pii] .
22. Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, et al. (2012) Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye's Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 10.1007/s11606-012-2098- 1 [doi].
23. Personal communication from DMA, October 2012
24. Elmholdt TR, Pedersen M, Jorgensen B, Sondergaard K, Jensen JD, et al. (2011) Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. Br J Dermatol 165: 828-836. 10.1111/j.1365-2133.2011.10465.x [doi].
25. Rydahl C, Thomsen HS, Marckmann P (2008) High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43: 141-144. 10.1097/RLI.0b013e31815a3407 [doi];00004424-200802000-00007 [pii].
26. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, et al. (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238-249. S0049-0172(05)00159-9 [pii];10.1016/j.semarthrit.2005.08.002 [doi]. (Pubitemid 43185214)
27. Lee CU, Wood CM, Hesley GK, Leung N, Bridges MD, et al. (2009) Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol 145: 1095-1102. 145/10/1095 [pii];10.1001/archdermatol.2009.232 [doi].
28. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, et al. (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253: 81-89. radiol.2531082160 [pii];10.1148/radiol.2531082160 [doi].
29. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA (2009) Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment- report of 33 cases. Radiology 250: 371-377. 250/2/371 [pii];10.1148/radiol.2502080498 [doi].
30. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, et al. (2008) Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 190: 736-741. 190/3/736 [pii];10.2214/AJR.07.3115 [doi]. (Pubitemid 351304519)
31. Bernstein EJ, Schmidt-Lauber C, Kay J (2012) Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol 26: 489-503. S1521-6942(12)00071-X [pii];10.1016/j. berh.2012.07.008 [doi].
32. Alhadad A, Sterner G, Svensson A, Alhadad H, Leander P (2012) Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scand J Urol Nephrol 46: 48-53. 10.3109/00365599.2011.621142 [doi].
33. Kendrick-Jones JC, Voss DM, De Zoysa JR (2011) Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006. Nephrology (Carlton) 16: 243-248. 10.1111/j.1440-1797.2010.01397.x [doi].
34. Hope TA, Herfkens RJ, Denianke KS, Leboit PE, Hung YY, et al. (2009) Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol 44: 135-139. 10.1097/RLI.0b013e31819343ba [doi].
35. Todd DJ, Kagan A, Chibnik LB, Kay J (2007) Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56: 3433-3441. 10.1002/art.22925 [doi]. (Pubitemid 47585439)
36. Personal communication with Anne Braae Olesen
37. Hoppe H, Spagnuolo S, Froehlich JM, Nievergelt H, Dinkel HP, et al. (2010) Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents. Eur Radiol 20: 595-603. 10.1007/s00330-009-1586-0 [doi].